Who owns PGNX - PROGENICS PHARMACEUTICALS IN - COM based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

PROGENICS PHARMACEUTICALS IN - COM (PGNX) Institutional Ownership

Q: What is CUSIP 743187106?

CUSIP 743187106 is the security identifier used in SEC filing datasets for PGNX - PROGENICS PHARMACEUTICALS IN - COM.

CUSIP: 743187106

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2020

Type / Class: Equity / COM
Symbol: PGNX

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 743187106:

Q3 2020 (0 holders) Q2 2020 (3 holders) Q1 2020 (121 holders) Q4 2019 (123 holders) Q3 2019 (127 holders) Q2 2019 (138 holders) Q1 2019 (137 holders) Q4 2018 (140 holders) Q3 2018 (137 holders) Q2 2018 (150 holders)

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2020 Q3	0	$0	-$177,000				0
2020 Q2	168,176	$177,000	-$221,048,659	$0	$0	$3.75	3
2020 Q1	58,363,453	$221,804,445	-$27,707,374	$128,000	$263,000	$3.80	121
2019 Q4	65,635,454	$334,041,057	-$11,617,319	$909,000	$593,000	$5.09	123
2019 Q3	67,698,181	$342,213,334	+$1,153,328	$703,000	$1,897,000	$5.06	127
2019 Q2	67,151,457	$414,048,433	-$334,800	$985,000	$2,218,000	$6.17	138
2019 Q1	68,380,216	$317,298,194	-$21,632,781	$819,000	$513,000	$4.64	137
2018 Q4	74,064,915	$310,896,095	-$25,616,323	$4,131,000	$4,031,000	$4.20	140
2018 Q3	77,827,881	$487,845,823	+$78,395,961	$8,170,000	$6,527,000	$6.27	137
2018 Q2	64,821,246	$521,178,303	+$4,962,303	$4,994,000	$10,646,000	$8.04	150
2018 Q1	64,277,556	$478,078,878	+$26,255,802	$9,849,000	$10,757,000	$7.46	144
2017 Q4	61,010,786	$362,979,514	-$13,457,081	$1,930,000	$1,233,000	$5.95	149
2017 Q3	57,900,241	$427,578,828	-$21,543,169	$2,462,000	$1,677,000	$7.36	132
2017 Q2	62,625,574	$425,255,374	-$18,131,482	$1,864,000	$1,596,000	$6.79	145
2017 Q1	64,792,905	$611,547,902	+$98,244,077	$3,091,000	$5,213,000	$9.44	154
2016 Q4	59,960,484	$518,057,513	+$2,600,473	$898,000	$1,841,000	$8.64	124
2016 Q3	60,301,771	$381,807,850	+$9,633,606	$498,000	$1,168,000	$6.33	111
2016 Q2	58,932,312	$248,849,563	-$6,973,074	$2,267,000	$109,000	$4.22	99
2016 Q1	60,452,860	$263,613,080	-$10,036,579	$476,000	$230,000	$4.36	116
2015 Q4	62,534,136	$383,315,230	-$30,298,692	$394,000	$318,000	$6.13	121
2015 Q3	67,404,510	$385,527,362	+$1,107,264	$636,000	$417,000	$5.72	130
2015 Q2	67,199,514	$501,258,644	+$20,429,134	$1,196,000	$4,800,000	$7.46	119
2015 Q1	65,121,961	$389,418,061	+$18,234,917	$1,559,000	$5,689,000	$5.98	106
2014 Q4	61,555,217	$464,831,168	+$47,488,135	$881,000	$2,086,000	$7.56	98
2014 Q3	56,456,747	$293,007,558	+$30,164,921	$1,054,000	$1,158,000	$5.19	76
2014 Q2	50,851,748	$219,162,625	-$5,776,419	$668,000	$597,000	$4.31	73
2014 Q1	52,249,198	$213,631,638	+$19,465,630	$915,000	$742,000	$4.09	86